Dr. Zhang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-2615
Summary
- Dr. Tian Zhang is an oncologist in Dallas, TX and is affiliated with UT Southwestern Medical Center. She received her medical degree from Harvard Medical School and has been in practice 14 years. She speaks multiple languages, including Chinese (Mandarin). She specializes in genitourinary cancers with experience in treatment of prostate, renal, bladder, and testicular cancers.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015- Duke University HospitalResidency, Internal Medicine, 2010 - 2012
- Duke University HospitalInternship, Internal Medicine, 2009 - 2010
Harvard Medical SchoolClass of 2009
Certifications & Licensure
TX State Medical License 2021 - 2026
NC State Medical License 2009 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) Start of enrollment: 2014 Mar 01
- Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer Start of enrollment: 2015 Apr 01
- Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO Start of enrollment: 2019 Nov 01
Publications & Presentations
PubMed
- Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma.Tian Zhang, Alan Tan, Amishi Y Shah, Gopa Iyer, Valerie Morris
The Oncologist. 2024-12-06 - 3 citationsFirst-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study.Talal El Zarif, Karl Semaan, Wanling Xie, Marc Eid, Martin Zarba
European Urology. 2024-12-01 - Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal C...Pedro Barata, Catherine Tangen, Melissa Plets, Ian M Thompson Jr, Vivek Narayan
Journal of Clinical Oncology. 2024-11-20
Abstracts/Posters
- Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2Tian Y Zhang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after ra...2019 ASCO Annual Meeting - 6/1/2019
- PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (All...2019 ASCO Annual Meeting - 6/1/2019
- Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
COVID-19 Vaccines for Patients with Cancer: Benefits Likely Outweigh RisksFebruary 27th, 2021
Case 1: Non-Muscle Invasive, BCG-Refractory Bladder CancerNovember 27th, 2019
The Kidney Cancer Association Announces Recipients for the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA)September 16th, 2019- Join now to see all
Professional Memberships
- Associate
- Member
- Member
- Member
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
